Minimized atrial pacing and atrial fibrillation burden in the DANPACE II trial Authors: Maria Hee Jung Park Frausing, Frederik Mikkelsen, Mads Brix Kronborg, Jacob Moesgaard Larsen, Katja Fiedler Holm, Andi Eie Albertsen, Lene Svendstrup, Ulrik Hintze, Ole Dyg Pedersen, Ulla Davidsen, Thomas Fischer, Jens Brock Johansen, Christian Gerdes, Jens Cosedis Nielsen Published: 2026 Introduction The DANPACE II trial showed that minimizing atrial pacing did not reduce the incidence of atrial fibrillation (AF) in patients with sinus node dysfunction (SND).1 The primary outcome was incident AF lasting ≥6 min, a relatively short-duration threshold that may not adequately capture the overall arrhythmic burden experienced by patients. Brief AF episodes may have limited clinical significance, particularly if they are infrequent or self-terminating, whereas AF burden integrates both frequency and duration.2 Emerging evidence indicates that adverse outcomes such as stroke, heart failure, and atrial remodelling correlate more strongly with cumulative AF duration than a binary classification of AF presence.3,4 An in-depth evaluation of AF burden in DANPACE II using data from remote monitoring (RM) systems has not previously been performed. This secondary analysis of the DANPACE II trial aimed to determine the influence of reduced atrial pacing on AF burden in patients with SND. Methods DANPACE II was a national, open-label, investigator-initiated, randomized controlled trial designed to investigate whether a reduction in atrial pacing reduced the incidence of AF (ClinicalTrials.gov no. NCT02034526).1 Patients were assigned to pacing at a base rate of 40 beats per minute (b.p.m.) without rate-adaptive pacing (DDD-40), or rate-adaptive pacing at a base rate of 60 b.p.m. (DDDR-60). We included all patients from DANPACE II with available RM data. Atrial fibrillation burden was assessed in patients with ≥1 adjudicated device-detected AF episode lasting ≥6 min and quantified as the cumulative duration of atrial high-rate episodes relative to total monitored time. Follow-up was set at maximum 2 years. Differences in AF burden between patients randomized to DDD-40 or DDDR-60 were assessed according to the intention-to-treat principle using a zero-inflated negative binomial regression model with monitoring time as the offset and a robust estimator of variance. Results are presented as incidence rate ratios (IRRs) and odds ratios (ORs) with 95% confidence intervals (CIs). This analysis was repeated with stratification for prior AF. Results We included 488 patients from the DANPACE II trial: 241 patients randomized to DDD-40 and 247 patients randomized to DDDR-60. Fifty-one patients were excluded due to unavailable RM data. Baseline characteristics were well-balanced between groups (Figure 1A). The median age was 74 [inter-quartile range (IQR) 67–79] years, 237 (49%) were women, and 276 (57%) had AF or atrial flutter at baseline. Fifteen patients withdrew before the study was finalized, and 31 patients died during follow-up. The median monitoring duration was 626 (IQR 637–731) days, and the median pacing percentage was 1% (IQR 0–14) and 49% (IQR 22–75) with DDD-40 vs. DDDR-60, respectively. (A) Baseline characteristics according to treatment allocation. (B) Results from the zero-inflated negative binomial regression model. (C) Atrial fibrillation burden according to treatment allocation in individual patients without prior AF. (D) Atrial fibrillation burden according to treatment allocation in patients with prior AF. In panels (C) and (D), each bar refers to one patient. AF, atrial fibrillation; AFL, atrial flutter; CI, confidence interval; LVEF, left ventricular ejection fraction; IRR, incidence rate ratio; OR, odds ratio. During follow-up, AF was detected in 232 (48%) patients, and the median AF burden was 2.1% (IQR 0.2–7.5%). In patients randomized to DDD-40, AF occurred in 117 (48%) patients with a median AF burden of 3.0% (IQR 0.2–8.1%). In patients randomized to DDDR-60, AF occurred in 115 (47%) patients with a median AF burden of 1.2% (IQR 0.2–6.3%). We observed no differences in neither AF detection nor burden between treatment groups (IRR 1.2, 95% CI 0.7–2.0 and OR 0.9, 95% CI 0.6–1.3) (Figure 1B). Atrial fibrillation was observed in 64 (23%) patients without prior AF (34 with DDD-40 vs. 30 with DDDR-60) compared with 168 (79%) patients with prior AF (83 with DDD-40 vs. 85 with DDDR-60) (Figure 1C, D). After stratification for baseline AF status, we observed no difference in AF detection rate (OR 0.8, 95% CI 0.5–1.5), but among patients with new-onset AF, DDD-40 pacing was associated with a significantly higher AF burden, IRR 5.3, 95% CI 1.3–21.1 (Figure 1B). No differences in AF detection or burden were observed for patients with prior AF. Discussion Consistent with the main analysis, minimized atrial pacing did not reduce AF burden in patients with SND. In patients without prior AF who developed new-onset AF, DDD-40 pacing was associated with a significantly higher AF burden, despite no detectable difference in AF incidence. The mechanisms underlying AF development are complex, but atrial dilatation and increased wall stress are associated with AF onset and may also promote its persistence.5–7 Likewise, comorbidities commonly linked to AF risk, including heart failure, hypertension, and valvular heart disease, contribute to increased atrial wall stretch.8 Non-physiologically slow heart rates in patients with DDD-40 programming may prolong atrial filling time, potentially contributing to atrial enlargement and a subsequent higher susceptibility to sustained or recurring AF.9,10 Interestingly, this difference in AF burden was not observed among patients with a history of AF at inclusion. One possible explanation could be more advanced atrial remodelling at baseline due to a longer history of AF in these patients, in which case the extent of atrial pacing is less likely to affect AF persistence or recurrence. Despite no difference in AF incidence in DANPACE II, the rate of syncope and presyncope was higher in patients assigned to DDD-40.1 Taken together, DDD-40 pacing in patients with SND appears associated with more adverse events, and in those with new-onset AF, a higher AF burden. This supports the use of pacing with rate response at higher base rates in this patient group. The key strengths of this study include its randomized comparison of two pacing strategies and the availability of precise AF assessment based on continuous rhythm monitoring from dual-chamber pacemakers. However, this was a post hoc analysis, crossovers during follow-up were not assessed, and subgroup analyses according to AF status were based on smaller samples with fewer events. Fifty-one patients from the original trial cohort were excluded due to missing RM data. However, absence of RM data was unlikely to be related to treatment allocation or the outcome, and therefore we do not believe this exclusion biased the estimate. Still, we emphasize that findings from this study are exploratory and require confirmation in larger prospective studies. Conclusion In the DANPACE II trial population, a strategy of minimized atrial pacing did not reduce the burden of AF. Subgroup analyses suggest that reduced atrial pacing may increase AF burden in patients with new-onset AF.